



Scientific Symposium of the WBMT

Hanoi, Vietnam, Saturday, November 12, 2011

www.wbmt.org



FINAL PROGRAM

Dear friends,

Haematopoietic stem cell transplantation has advanced to the level of being the only curative treatment for many haematological and non-haematological diseases. The frequency of stem cell transplantation varies considerably among the world regions and is dependent upon the national income and the resources devoted to health expenditures.

The primary mission of the Worldwide Network for Blood & Marrow Transplantation (WBMT, www.wbmt.org), a federation of eighteen (18) international societies involved in stem cell transplantation around the world, is to establish broad standards and assist countries with limited resources in development and performance of this curative treatment.

To this end, WBMT, in association with the World Health Organization (WHO), has planned this meeting in Vietnam with the participation of health authorities from at least sixteen (16) countries with restricted resources and low transplant frequency (Gratwohl JAMA 2010). It is our goal not only to guide physicians to optimize their current stem cell transplantation activities but also to create awareness among policy makers about the value of stem cell transplantation so that these activities can be expanded.

Representatives from established transplant centers in countries with limited resources will also participate, with the goal of optimizing their own programs and guiding countries without experience to establish effective and resource sparing programs.

On the third of the three day Program, a more conventional, *Scientific Symposium* will be held that will focus on stem cell transplantation. This meeting presents a unique opportunity to educate potential new markets about the goods and services offered and we warmly invite you to participate.

We are looking forward to an interesting meeting and we appreciate your attendance.

Sincerely



Dietger Niederwieser
President



Yoshihisa Kodera
Vice President



Dennis Confer
Secretary/Treasurer



Hildegard Greinix
for Past President position

PROGRAM OF THE WBMT SYMPOSIUM

- 08:30 – 10:30 **Optimal Stem Cell Source in Allogeneic HCT**
*Chairs: Yoshihisa Kodera, Nagoya, Japan
Bach Quoc Khanh, Hanoi, Vietnam*
- 08:30 **Bone marrow vs. peripheral blood**
Daniel Weisdorf, Minneapolis, USA
- 09:00 **HCT with cord blood stem cells**
Eliane Gluckman, Paris, France
- 09:30 **Cord blood transplantation for adult patients**
Shuichi Taniguchi, Tokyo, Japan
- 10:00 **Haplo-identical HCT from family members**
Hiroyasu Ogawa, Osaka, Japan
- 10:30 – 11:00 Coffee/Tea Break
- 11:00 – 12:30 **Complications of HCT**
*Chairs: Tran Van Binh, Ho Chi Minh City, Vietnam
Alejandro Madrigal, London, UK*
- 11:00 **Graft-versus-host disease**
Hildegard Greinix, Vienna, Austria
- 11:30 **Infectious complications after HCT**
Shinichiro Okamoto, Tokyo, Japan
- 12:00 **Impact of reduced-intensity conditioning on outcome of HCT**
Dietger Niederwieser, Leipzig, Germany
- 12:30 – 13:30 Lunch Break
- 13:30 – 14:30 **HCT in Non-Malignant Disease**
*Chairs: Nguyen Anh Tri, Hanoi, Vietnam
Dennis Confer, Minneapolis, USA*
- 13:30 **HCT for bone marrow failures**
Joerg Halter, Basel, Switzerland
- 13:50 **HCT in hemoglobinopathies**
Alok Srivastava, Vellore, India
- 14:10 **HCT in severe aplastic anemia**
Seiji Kojima, Japan
- 14:30 – 15:00 Coffee/Tea Break
- 15:00 – 17:00 **HCT in Malignant Disease**
*Chairs: Nguyen Tan Binh, Ho Chi Minh City, Vietnam
Carlheinz Mueller, Ulm, Germany*
- 15:00 **HCT in leukaemia**
Marcelo Pasquini, Milwaukee, USA
- 15:30 **HCT in lymphoma**
Jeffrey Szer, Parkville, Australia
- 16:00 **HCT in myeloma**
Dietger Niederwieser, Leipzig, Germany

Sponsors

The organizers express their thanks and appreciation to all the companies who made the organization of the WBMT Symposium possible.

Astra Zeneca Japan

CaridianBCT (Asia Pacific) Limited

Cephalon GmbH

Chugai Japan

Gentium SpA

Genzyme Japan

Glaxo Smith Kline Japan

Janssen Pharma Japan

Japan Chemical Research

Miltenyi Biotec GmbH

Novartis Japan

Pfizer Japan

Soligenix Inc.

